Last reviewed · How we verify
Sham laser plus topical clonazepam
Sham laser plus topical clonazepam combines a placebo laser procedure with a benzodiazepine applied to the skin to reduce anxiety and pain symptoms.
Sham laser plus topical clonazepam combines a placebo laser procedure with a benzodiazepine applied to the skin to reduce anxiety and pain symptoms. Used for Anxiety disorders (topical application), Neuropathic pain or localized pain conditions.
At a glance
| Generic name | Sham laser plus topical clonazepam |
|---|---|
| Sponsor | Universidad Nacional Autonoma de Mexico |
| Drug class | Benzodiazepine (topical) + sham procedure |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Pain Management / Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clonazepam is a benzodiazepine that enhances GABAergic neurotransmission in the central nervous system, reducing anxiety and providing anxiolytic effects. When applied topically, it may provide localized anxiolytic and muscle-relaxant effects. The sham laser component serves as a control or placebo element in the treatment regimen.
Approved indications
- Anxiety disorders (topical application)
- Neuropathic pain or localized pain conditions
Common side effects
- Drowsiness
- Dizziness
- Local skin irritation
- Dependence risk (benzodiazepine)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: